Astellas Pharma Inc. and Pfizer Inc. have announced that their antibody-drug conjugate PADCEV (enfortumab vedotin), in combination with the PD-1 inhibitor pembrolizumab (marketed as Keytruda by Merck), met key survival endpoints in the Phase 3 EV-304 trial. In cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC), the combination significantly improved both event-free survival and overall survival in the neoadjuvant and adjuvant setting, compared to the current standard of care—gemcitabine and cisplatin.
This platinum-free regimen now joins the previously published EV-303 (KEYNOTE-905) data, which led to U.S. regulatory approval of the combination in cisplatin-ineligible MIBC patients. Together, these datasets position PADCEV plus pembrolizumab as a potentially universal perioperative option in early-stage urothelial cancer, regardless of cisplatin eligibility.
The oncology community has been closely monitoring this combination as a candidate to replace, not just supplement, platinum-based chemotherapy in bladder cancer. With the EV-304 results now hitting their predefined endpoints, Astellas and Pfizer are preparing to engage global regulators in discussions that could culminate in a broad label expansion. But beyond regulatory filing plans, the trial signals deeper implications for clinical practice, treatment paradigms, and payer frameworks.
How EV-304 results strengthen the regulatory case for cisplatin-eligible patients
While the EV-303 trial broke ground by offering a platinum-free neoadjuvant option for patients traditionally underserved by cisplatin-based regimens, the EV-304 results extend that vision to a much larger and historically treated population. The clinical design of EV-304 compared perioperative PADCEV plus pembrolizumab with the long-standing gemcitabine-cisplatin combination, with curative-intent cystectomy performed after systemic therapy.
The trial met its primary endpoint of event-free survival, defined by time to local recurrence, metastasis, or death. It also achieved statistical significance on overall survival, a key secondary endpoint. An additional secondary endpoint, pathologic complete response at the time of surgery, was also met.
These data suggest that the PADCEV-pembrolizumab combination is not merely an alternative for cisplatin-ineligible patients, but a superior option in terms of efficacy for cisplatin-eligible patients as well. If supported by regulators, this would effectively allow oncologists to offer a single immunotherapy-ADC combination across the entire early-stage MIBC population.
What differentiates this regimen from platinum-based neoadjuvant chemotherapy
At the mechanistic level, PADCEV targets Nectin-4, a surface protein highly expressed in bladder cancer cells. The drug delivers monomethyl auristatin E, a cytotoxic payload, directly into tumor cells. Pembrolizumab, already widely used in metastatic urothelial cancer, restores immune surveillance by blocking PD-1 checkpoint inhibition.
By combining these agents, the regimen delivers both directed cytotoxicity and immune activation. This contrasts with the non-specific mechanism of action in cisplatin-based regimens, which often require robust renal function and are associated with systemic toxicity. For many patients, particularly older adults with borderline renal status, platinum-based therapy is not feasible.
Although the EV-304 trial was limited to patients eligible for cisplatin, its success raises the question of whether platinum agents can remain the standard when a non-platinum regimen demonstrates superior survival and safety in a broader patient population.
What safety concerns may complicate adoption despite strong efficacy
The adverse event profile, while generally consistent with prior PADCEV-pembrolizumab studies, introduces important considerations. In EV-303 and related trials, skin reactions were among the most frequently reported adverse events, with serious events including Stevens-Johnson syndrome and toxic epidermal necrolysis occurring in rare but fatal cases.
Peripheral neuropathy was also a significant issue. In perioperative settings, the emergence of grade 2 or 3 neuropathy prior to surgery raises logistical concerns. EV-303 data revealed that 4.2 percent of patients could not proceed to cystectomy after neoadjuvant treatment due to treatment-emergent complications. These interruptions, though uncommon, can undermine the curative intent of early surgery in MIBC.
Pneumonitis, infusion reactions, and hyperglycemia also featured in the safety dataset, albeit at expected frequencies. Regulatory discussions are likely to focus on how these events were managed, the rates of discontinuation or dose modifications, and their impact on surgical timing.
Why clinicians may recalibrate neoadjuvant pathways before full approval
Although the combination is not yet approved for cisplatin-eligible patients, its use in the ineligible subgroup is already shaping expectations. Academic centers and high-volume community oncology networks that have access to both agents may begin rethinking their treatment pathways even before global health authorities issue a verdict on EV-304.
The timing of surgery is central to bladder cancer outcomes. Given that immunotherapy may offer more durable control and less systemic toxicity, some clinicians could favor the biologics-based approach if supported by multidisciplinary consensus and institutional review.
Furthermore, the ability to extend systemic therapy into the adjuvant phase without changing agents could support longer-term disease control. With the same combination used before and after surgery, treatment continuity becomes easier to manage, especially in outpatient or hybrid care models.
What regulators and payers will focus on as filings move forward
For health authorities and reimbursement agencies, the most likely focus areas include a detailed assessment of the benefit-risk ratio across different patient subpopulations, particularly in terms of tolerability versus efficacy when compared to existing standards. They will also scrutinize comparative long-term survival and recurrence rates, weighing whether the improved endpoints seen in clinical trials can be replicated in real-world settings over extended follow-up periods.
Biomarker relevance will be another critical area, especially the role of Nectin-4 expression as a predictive or prognostic factor for treatment response, which could shape both patient selection and reimbursement criteria. Cost-effectiveness is expected to receive particular attention, as the PADCEV and pembrolizumab combination will be evaluated against the much lower cost of generic platinum-based chemotherapy, including its impact on hospital stays, supportive care, and complication management.
Finally, payers and regulators will likely evaluate the real-world feasibility of integrating both agents into the perioperative workflow, including the logistical challenges of scheduling infusions, monitoring for immune-related adverse events, and coordinating with surgical timelines in both academic and community oncology settings.
In the U.S. market, the precedent of accelerated approval in the cisplatin-ineligible setting may influence how regulators approach the broader filing. European regulators, typically more conservative with early oncology approvals, will likely seek longer-term data and post-approval commitments.
Health technology assessment bodies in the United Kingdom, Germany, and Canada may also question the pricing structure and resource utilization implications, especially if uptake shifts patients away from lower-cost cisplatin protocols.
How this reshapes the competitive landscape in early-stage urothelial cancer
Should PADCEV plus pembrolizumab receive full approval for cisplatin-eligible MIBC, the commercial and clinical competitive landscape will shift dramatically. Pembrolizumab is already entrenched in the metastatic setting, while enfortumab vedotin has demonstrated efficacy both as monotherapy and in combination in later-line disease.
Competitor checkpoint inhibitors such as nivolumab and atezolizumab have not shown comparable results in the perioperative setting. Likewise, other ADCs in the bladder cancer pipeline remain in earlier stages of development or lack broad biomarker expression profiles like Nectin-4.
From a strategic perspective, Pfizer and Astellas may now position the PADCEV-pembrolizumab combination as a backbone therapy in urothelial cancer. Expansion into earlier stages or maintenance therapy settings would be a natural next step.
What this means for patients and the future of bladder cancer care
For patients, the most meaningful shift is the prospect of a more tolerable, more effective, and more accessible perioperative treatment. Platinum chemotherapy, while effective in some patients, excludes a significant proportion due to renal function, age, or comorbidity.
By demonstrating survival improvement without cisplatin, PADCEV plus pembrolizumab opens the door to more equitable care. This is particularly relevant in aging populations, where bladder cancer incidence is high and comorbidities common.
In clinical practice, multidisciplinary teams will need to weigh the logistical complexities of coordinating ADC administration, managing immune-related adverse events, and maintaining surgical readiness. But if the survival data from EV-304 is confirmed in real-world outcomes, the effort may be well worth it.
PADCEV plus Keytruda meets survival endpoints in cisplatin-eligible bladder cancer patients added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →